1. Home
  2. REE vs PMN Comparison

REE vs PMN Comparison

Compare REE & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo REE Automotive Ltd.

REE

REE Automotive Ltd.

HOLD

Current Price

$0.67

Market Cap

21.7M

ML Signal

HOLD

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

HOLD

Current Price

$11.05

Market Cap

23.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REE
PMN
Founded
2011
2004
Country
Israel
Canada
Employees
N/A
N/A
Industry
Auto Manufacturing
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
21.7M
23.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
REE
PMN
Price
$0.67
$11.05
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
$11.75
$72.67
AVG Volume (30 Days)
132.2K
17.9K
Earning Date
03-16-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$207,000.00
N/A
Revenue This Year
$327.73
N/A
Revenue Next Year
$36,888.82
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.53
$6.27
52 Week High
$9.53
$39.75

Technical Indicators

Market Signals
Indicator
REE
PMN
Relative Strength Index (RSI) 37.14 74.00
Support Level $0.69 $8.96
Resistance Level $0.78 $10.18
Average True Range (ATR) 0.07 0.65
MACD -0.01 0.12
Stochastic Oscillator 21.31 85.03

Price Performance

Historical Comparison
REE
PMN

About REE REE Automotive Ltd.

REE Automotive Ltd is an automotive technology company focused on building commercial electric vehicles controlled fully by-wire. The company is in early stages of commercialization and develop and produce software-defined vehicle (SDV) technology that manages vehicle operations and features through proprietarily-developed software. The company has geographical preference in Israel, Germany, United States, United Kingdom, and other regions.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.

Share on Social Networks: